ReviewMolecular neurobiology2013
Current progress for the use of miRNAs in glioblastoma treatment.
Review in Molecular neurobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Non-coding RNAs as Key Regulators of the Notch Signaling Pathway in Glioblastoma: Diagnostic, Prognostic, and Therapeutic Targets.CNS & neurological disorders drug targets · 2024Review
- Morusin Enhances Temozolomide Efficiency in GBM by Inducing Cytoplasmic Vacuolization and Endoplasmic Reticulum Stress.Journal of clinical medicine · 2022Article
- Article
- Long Noncoding RNA H19 Promotes Proliferation and Invasion in Human Glioma Cells by Downregulating miR-152.Oncology research · 2018Article
- MircoRNA-1275 promotes proliferation, invasion and migration of glioma cells via SERPINE1.Journal of cellular and molecular medicine · 2018Article
- MicroRNA-598 Inhibits Cell Proliferation and Invasion of Glioblastoma by Directly Targeting Metastasis Associated in Colon Cancer-1 (MACC1).Oncology research · 2018Article
- Role of miR-613 as a tumor suppressor in glioma cells by targeting SOX9.OncoTargets and therapy · 2018Article
- MicroRNA-mRNA expression profiles associated with medulloblastoma subgroup 4.Cancer management and research · 2018Article
- MicroRNA-671-3p promotes proliferation and migration of glioma cells via targeting CKAP4.OncoTargets and therapy · 2018Article
- Nanoparticulate Tetrac Inhibits Growth and Vascularity of Glioblastoma Xenografts.Hormones & cancer · 2017Article
- MicroRNA-1468-5p inhibits glioma cell proliferation and induces cell cycle arrest by targeting RRM1.American journal of cancer research · 2017Article
- The role of microRNAs in intrahepatic cholangiocarcinoma.Journal of cellular and molecular medicine · 2017Review
- MicroRNA-520d-5p inhibits human glioma cell proliferation and induces cell cycle arrest by directly targeting PTTG1.American journal of translational research · 2017Article
- Article
- MicroRNA-141 inhibits glioma cells growth and metastasis by targeting TGF-β2.American journal of translational research · 2016Article
- MicroRNA-217 inhibits cell proliferation and invasion by targeting Runx2 in human glioma.American journal of translational research · 2016Article
- Microarray Analysis in Glioblastomas.Methods in molecular biology (Clifton, N.J.) · 2016Article
- miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.Oncotarget · 2015Article
- MicroRNA expression and its implications for diagnosis and therapy of gallbladder cancer.Oncotarget · 2015Review
- MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme--a systematic overview.Molecular neurobiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a highly aggressive brain cancer with the worst prognosis of any central nervous system disease despite intensive multimodal therapy. Inevitably, glioblastoma is fatal, with recurrence of treatment-resistant tumour growth at distal sites leading to an extremely low median survival rate of 12-15 months from the time of initial diagnosis. With the advent of microarray and gene profiling technology, researchers have investigated trends in genetic alterations and, in this regard, the role of dysregulated microRNAs (highly conserved endogenous small RNA molecules) in glioblastoma has been studied with a view to identifying novel mechanisms of acquired drug resistance and allow for development of microRNA (miRNA)-based therapeutics for GBM patients. Considering the development of miRNA research from initial association to GBM to commercial development of miR-based therapeutics in less than a decade, it is not beyond reasonable doubt to anticipate significant advancements in this field of study, hopefully with the ultimate conclusion of improved patient outcome. This review discusses the recent advancements in miRNA-based therapeutic development for use in glioblastoma treatment and the challenges faced with respect to in vivo and clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.